You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 10, October 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Cost-effectiveness of intra-arterial thrombolytic therapy

L. J. Dacey, R. W. Dow, M. D. McDaniel, D. B. Walsh, R. M. Zwolak and J. L. Cronenwett
Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Hanover, NH 03756.

We reviewed the clinical course of 23 patients who received 24 intra-arterial infusions of either streptokinase or urokinase to treat 14 arteries and ten arterial grafts that were occluded due to primary thrombosis (22) or artery-artery embolism (two). Time from symptom onset to treatment was one to 28 days (mean, 11 days). Five infusions (21%) were completely successful since symptoms were eliminated without subsequent operation. Seven infusions (29%) were partially successful since thrombolysis aided, limited, or postponed subsequent surgery. Six infusions (25%) were failures since thrombolysis or clinical improvement did not occur and surgery was required. Six infusions (25%) were associated with thrombolytic complications that required urgent operation (less severe complications occurred in an additional 17% of cases [4/24]). Of the 19 patients without complete success after thrombolytic therapy, 16 underwent surgery during the same admission, two were not operable due to distal disease, and one declined operation. Of the 16 operations, 15 (94%) were successful in restoring graft or artery patency and achieving limb salvage, whereas one failed. In the 12 patients with failure or major complications of thrombolytic treatment, all had successful surgical outcome without morbidity. The actual mean cost of thrombolytic treatment was $8200 per patient and was comparable with the actual mean cost of subsequent surgical treatment in the 16 patients who required operation ($8900 per patient). The effective cost of thrombolytic and surgical treatment was calculated by dividing the actual costs by the proportion of successful cases. The effective cost of thrombolytic therapy per complete success was $39,200 and per complete or partial success was $16,500. This was significantly more than the effective cost of $9400 per complete success of surgical therapy.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-Term Results After Percutaneous Low-Dose Streptokinase Treatment for Acute Arterial Thrombosis
Yilmaz et al.
VASC ENDOVASCULAR SURG 2000;34:225-230.
ABSTRACT  

Outcome and Cost Comparison of Percutaneous Transluminal Renal Angioplasty, Renal Arterial Stent Placement, and Renal Arterial Bypass Grafting
Xue et al.
Radiology 1999;212:378-384.
ABSTRACT | FULL TEXT  

Effect on Thrombolysis and its Complication of Graft Occlusion and Specific Risk Factors
Ikeda et al.
VASC ENDOVASCULAR SURG 1995;29:443-448.
ABSTRACT  

Thrombolytic Therapy and Modern Vascular Surgery: An Overview
Harris and Porter
PERSPECT VASC SURG ENDOVASC THER 1989;2:40-63.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.